PBO | FEN 150 mg QD | FEN 200 mg BID | |
---|---|---|---|
SRI-4 Response (%) at W48 | 44 n=84 | 51 n=87 | 52 n=88 |
SRI-4 Response (%) in Baseline Subgroups | |||
At least 1 BILAG A | 48 n=42 | 54 n=39 | 59 n=46 |
At least 1 BILAG A and SLEDAI increased DNA binding | 37 n=19 | 53 n=17 | 65 n=26 |
SLEDAI arthritis with at least 4 swollen joints | 39 n=57 | 50 n=54 | 57 n=54 |
SLEDAI arthritis with at least 4 tender joints | 39 n=71 | 53 n=70 | 59 n=69 |
CLASI >=10 | 21 n=14 | 36 n=11 | 31 n=16 |